Recent Developments in Myelodysplastic Syndromes
This book deals with the rapid progress in the area of myelodysplastic syndromes (MDS). MDS are a group of age-associated heterogeneous malignant bone marrow stem cell disorders. MDS are characterized by ineffective hematopoiesis, which leads to refractory cytopenias and to clonal instability. Patie...
שמור ב:
| פורמט: | Online |
|---|---|
| שפה: | אנגלית |
| יצא לאור: |
IntechOpen
2023
|
| נושאים: | |
| גישה מקוונת: | ONIX_20231201_9781789854787_1750 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
| _version_ | 1869517866560126976 |
|---|---|
| collection | Directory of Open Access Books |
| description | This book deals with the rapid progress in the area of myelodysplastic syndromes (MDS). MDS are a group of age-associated heterogeneous malignant bone marrow stem cell disorders. MDS are characterized by ineffective hematopoiesis, which leads to refractory cytopenias and to clonal instability. Patients with MDS have myeloid dysplasia, intramedullary apoptosis and an increased risk of transformation to acute myeloid leukemia (AML). The use of next generation sequencing has allowed for the identification of molecular mutations in several genes in about 90% of MDS patients. Several mutations will likely be incorporated into future prognostic scoring systems for MDS. About 50% of MDS cases are characterized by the presence of cytogenetic abnormalities. The correct morphological and cytogenetic analysis interpretation plays an important role in diagnosis and prognosis of these disorders. Cell death and an inflammatory gene signature are associated with MDS. Better understanding of the genetic and molecular mechanisms of MDS pathogenesis provides an opportunity for new treatment strategies to be developed. Promising novel therapies targeting pathophysiological mechanisms of MDS are being studied but the drugs currently used in MDS therapy remain limited. The only curative therapy for MDS is allogeneic hematopoietic stem cell transplantation. Recent advances in strategies to minimize transplant-related toxicity make this treatment possible for more MDS patients who are sufficiently fit. |
| format | Online |
| id | doab-20.500.12854ir-130641 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1306412024-03-31T22:45:52Z Recent Developments in Myelodysplastic Syndromes Fuchs, Ota cytokines, pathogenesis, micrornas, dendritic cells, behçet’s disease, vasculitis thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology This book deals with the rapid progress in the area of myelodysplastic syndromes (MDS). MDS are a group of age-associated heterogeneous malignant bone marrow stem cell disorders. MDS are characterized by ineffective hematopoiesis, which leads to refractory cytopenias and to clonal instability. Patients with MDS have myeloid dysplasia, intramedullary apoptosis and an increased risk of transformation to acute myeloid leukemia (AML). The use of next generation sequencing has allowed for the identification of molecular mutations in several genes in about 90% of MDS patients. Several mutations will likely be incorporated into future prognostic scoring systems for MDS. About 50% of MDS cases are characterized by the presence of cytogenetic abnormalities. The correct morphological and cytogenetic analysis interpretation plays an important role in diagnosis and prognosis of these disorders. Cell death and an inflammatory gene signature are associated with MDS. Better understanding of the genetic and molecular mechanisms of MDS pathogenesis provides an opportunity for new treatment strategies to be developed. Promising novel therapies targeting pathophysiological mechanisms of MDS are being studied but the drugs currently used in MDS therapy remain limited. The only curative therapy for MDS is allogeneic hematopoietic stem cell transplantation. Recent advances in strategies to minimize transplant-related toxicity make this treatment possible for more MDS patients who are sufficiently fit. 2023-12-01T18:00:32Z 2023-12-01T18:00:32Z 2019 book ONIX_20231201_9781789854787_1750 9781789854787 9781789854770 9781839620409 https://directory.doabooks.org/handle/20.500.12854/130641 eng image/jpeg n/a https://www.intechopen.com/books/7138 https://mts.intechopen.com/storage/books/7138/authors_book/authors_book.pdf IntechOpen IntechOpen 10.5772/intechopen.73936 10.5772/intechopen.73936 78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6 9781789854787 9781789854770 9781839620409 IntechOpen 120 open access |
| spellingShingle | cytokines, pathogenesis, micrornas, dendritic cells, behçet’s disease, vasculitis thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Recent Developments in Myelodysplastic Syndromes |
| title | Recent Developments in Myelodysplastic Syndromes |
| title_full | Recent Developments in Myelodysplastic Syndromes |
| title_fullStr | Recent Developments in Myelodysplastic Syndromes |
| title_full_unstemmed | Recent Developments in Myelodysplastic Syndromes |
| title_short | Recent Developments in Myelodysplastic Syndromes |
| title_sort | recent developments in myelodysplastic syndromes |
| topic | cytokines, pathogenesis, micrornas, dendritic cells, behçet’s disease, vasculitis thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | cytokines, pathogenesis, micrornas, dendritic cells, behçet’s disease, vasculitis thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20231201_9781789854787_1750 |